Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Tau biomarkers

Topic: Brain proteins, microglia and lab models

Objective Debate surrounds the role of chronic pain as a risk factor for cognitive decline and dementia. This study aimed at examining the association of chronic pain with biomarkers of neurodegeneration using data from the Alzheimer's Disease Neuroimaging Initiative. Methods Participants were classified using the ATN (amyloid, tau, neurodegeneration) classification.

Key findings

Why it matters

This study examined whether chronic pain is associated with CSF markers of neurodegeneration, microglial activation and inflammation, and with cognitive function. It investigates chronic pain as a possible risk factor but does not test any treatment or show that treating pain prevents dementia.

Study details

How this study scored 63/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 3 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record left out, no data; Institution's track record 2 of 3; Multi-centre collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 60 of the 96 points it could be judged on, which is 63 of 100. Total 63 of 100.60 of the 96 points we could judge = 63 of 100

Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 60 of the 96 points we could judge it on, which is 63 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Annals of neurology)
Journal's citation record 3 / 4 Annals of Neurology: journal h-index 437 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2023 — within 6 year(s) of the newest study here
Sample size 2 / 4 995 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 24 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.8 citations a year over 5 year(s) since 2023
Impact for its field and year 3 / 6 Cited 4.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 2 / 4 Cited 24 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 2 / 3 Imperial College London: institution h-index 1,744 (OpenAlex)
Multi-centre collaboration 3 / 3 OpenAlex lists 16 institution(s) in 6 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 37787094)
Free to read 0 / 2 Behind a paywall — scores zero
Points 60 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 60 of the 96 points we could judge it on is 63 out of 100.
Total 63 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Sadlon, A., Takousis, P., Ankli, B., Alexopoulos, P., Perneczky, R., & Alzheimer's Disease Neuroimaging Initiative. (2023). Association of Chronic Pain with Biomarkers of Neurodegeneration, Microglial Activation, and Inflammation in Cerebrospinal Fluid and Impaired Cognitive Function. Annals of neurology. https://doi.org/10.1002/ana.26804

Vancouver

Sadlon A, Takousis P, Ankli B, Alexopoulos P, Perneczky R, Alzheimer's Disease Neuroimaging Initiative. Association of Chronic Pain with Biomarkers of Neurodegeneration, Microglial Activation, and Inflammation in Cerebrospinal Fluid and Impaired Cognitive Function. Annals of neurology. 2023. doi:10.1002/ana.26804. PMID: 37787094.

BibTeX

@article{sadlon2023-37787094,
  author  = {Sadlon, A. and Takousis, P. and Ankli, B. and Alexopoulos, P. and Perneczky, R. and {Alzheimer's Disease Neuroimaging Initiative}},
  title   = {{Association of Chronic Pain with Biomarkers of Neurodegeneration, Microglial Activation, and Inflammation in Cerebrospinal Fluid and Impaired Cognitive Function}},
  journal = {Annals of neurology},
  year    = {2023},
  doi     = {10.1002/ana.26804},
  pmid    = {37787094},
  url     = {https://doi.org/10.1002/ana.26804}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Tau biomarkers

Also tagged “biomarkers”

821 studies in the library carry the topic tag “biomarkers”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →